DCTPep ID  DCTPep01278

Peptide Name   Sequence 27 from Patent US 20060122119

Sequence  PRLPSSADVEFCL

Sequence Length  13

UniProt ID  P11344  Q8MIU0  P54834  Q9BDE0  P55033  P14679 

PubChem CID  Not available

Origin  Homo sapiens

Type  Native peptide

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

PDB ID  Not available

Predicted Structure  DCTPep01278

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L

Grand average of hydropathicity (GRAVY)  0.200

Half Life 
  >20 hours (mammalian reticulocytes, in vitro).
  >20 hours (yeast, in vivo).
  ? (Escherichia coli, in vivo).

Extinction coefficients 
  Ext. coefficient 0
  Abs 0.1% (=1 g/l) 0.000, assuming all pairs of Cys residues form cystines
  Ext. coefficient 0
  Abs 0.1% (=1 g/l) 0.000, assuming all Cys residues are reduced

Amino acid distribution

Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2006/0122119 A1

Patent Title  Peptides for use in antitumor immunotherapy.

Other Iinformation  Granted Patent Family: 10s / 10ex; Family Jurisdictions: CA, AU, FR, WO, US, EP, JP; Legal Status: Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002

Other Published ID  CA2477762A1  EP1481009A2  WO2003074565A2  WO2003074565A3